The novel crystalline amlodipine benzenesulfonate dihydrate of high purity is disclosed, as well as the process for preparation of the novel crystalline amlodipine benzenesulfonate dihydrate of high purity and the crystalline amlodipine benzenesulfonate monohydrate of high purity, suitable for the preparation of pharmaceutical formulations for the treatment of cardiac diseases or hypertension, and their use as intermediate compounds in the improved process of purification of the nonhydrate benzenesulfonate (besylate) salt of amlodipine.The process for preparation of the crystalline amlodipine benzenesulfonate dihydrate is carried in the way that from the C1-C5 alcoholic solution of amlodipine benzenesulfonate with water while stirring at a temperature of 20°C or lower the crystals of pure amlodipine benzenesulfonate dihydrate are separated, and isolated.The process for preparation of the crystalline amlodipine benzenesulfonate monohydrate is carried in the way that from the C1-C5 alcoholic solution of amlodipine benzenesulfonate with water while stirring at a temperature of 30°C or higher the crystals of pure amlodipine benzenesulfonate monohydrate are separated, and isolated.
揭示了高纯度的新型结晶
氨氯地平苯磺酸苄
水合物,以及制备高纯度的新型结晶
氨氯地平苯磺酸苄
水合物和高纯度的结晶
氨氯地平苯磺酸苄单
水合物的过程,适用于制备用于治疗心脏疾病或高血压的药物配方,并将它们用作改进的非
水合物
苯磺酸苄酯盐(besylate)的
氨氯地平纯化过程中的中间化合物。制备结晶
氨氯地平苯磺酸苄
水合物的过程是这样进行的:在20°C或更低温度下,从
氨氯地平苯磺酸苄的C1-C5醇溶液中加入
水搅拌,分离并提取出纯净的
氨氯地平苯磺酸苄
水合物晶体。制备结晶
氨氯地平苯磺酸苄单
水合物的过程是这样进行的:在30°C或更高温度下,从
氨氯地平苯磺酸苄的C1-C5醇溶液中加入
水搅拌,分离并提取出纯净的
氨氯地平苯磺酸苄单
水合物晶体。